Cryoprecipitate

From Wikipedia, the free encyclopedia
Jump to: navigation, search

Cryoprecipitate, also called cryo for short, is a frozen blood product prepared from blood plasma. To create cryoprecipitate, fresh frozen plasma is centrifuged and the precipitate is collected. It is often transfused as a four- to six-unit pool instead of as a single product. One of the most important constituents is factor VIII (also called antihaemophilic factor or AHF), which is why cryoprecipitate is sometimes called, or refined into, cryoprecipitated antihaemophilic factor or cryoprecipitated AHF. In many clinical contexts, use of whole cryoprecipitate has been replaced with use of clotting factor concentrates made therefrom, but the whole form is still routinely stocked by many hospital blood banks.

Unlike with use of fresh frozen plasma, cross-matching (compatibility testing) is not strictly necessary, but cryo is given as ABO compatible when possible.

Composition[edit]

Each unit (around 10 to 15 mL) typically provides:[1]

Cryoprecipitate also contains fibronectin; however there are no clear indications for fibronectin replacement.

US standards require manufacturers to test at least four units each month, and the products must have an average of 150 mg or more of fibrinogen and 80 IU of factor VIII.[2] Individual products may actually have less than these amounts as long as the average remains above these minimums. Typical values for a unit are substantially higher, and aside from infants it is rare to transfuse just one unit.

Indications[edit]

Indications for giving cryoprecipitate include:[3]

Adverse effects[edit]

Adverse effects reported with the usage of cryoprecipitate include hemolytic transfusion reactions, febrile non-hemolytic reactions, allergic reactions (ranging from urticaria to anaphylaxis), septic reactions, transfusion related acute lung injury, circulatory overload, transfusion-associated graft-versus-host disease, and post-transfusion purpura.[4]

References[edit]

  1. ^ "CRYO (cryoprecipitate) pharmacology". Medscape. 
  2. ^ "Circular of Information For the Use of Human Blood and Blood Components" (PDF). Archived from the original (PDF) on 2008-02-27. Retrieved 2008-02-28. 
  3. ^ Erber WN, Perry DJ (2006). "Plasma and plasma products in the treatment of massive haemorrhage". Best Pract Res Clin Haematol. 19 (1): 97–112. PMID 16377544. doi:10.1016/j.beha.2005.01.026. 
  4. ^ "CRYO (cryoprecipitate) Adverse Effects". Medscape.